Skip to content

Frontlight ResearchEarly access

Trial site

Linyi People's Hospital

Linyi, 276001, ChinaNot linked to an institution yet

39running trials
12closed trials

The trials here

What the 51 trials at this site are about, from their registry records.

Conditions: Stroke20 trials
Lung cancer5 trials
Gastric and oesophageal cancer4 trials
Atrial fibrillation3 trials
COPD2 trials
Coronary artery disease2 trials
Hepatitis B2 trials
IgA nephropathy2 trials
Liver and biliary tract cancer2 trials
Bladder cancer1 trial
Colorectal cancer1 trial
Deep vein thrombosis and pulmonary embolism1 trial
and 13 more
Phase: Phase 323 trials
Phase 212 trials
Phase 12 trials
Phase 2/32 trials
Phase 1/21 trial
Status: Recruiting17 trials
Not yet recruiting13 trials
Completed11 trials
Active, not recruiting9 trials
Terminated1 trial
Lead sponsor: Capital Medical University5 trials
Beijing Tiantan Hospital4 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 trials
Chinese University of Hong Kong2 trials
Qilu Hospital of Shandong University2 trials
and 33 more

Running trials

Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source
Contact: Ding Ma, PhD
Not yet recruiting
Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
NCT07917078· Phase 3· China National Center for Cardiovascular Diseases· Source
Contact: Le Kang, Prof.
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309· Phase 1· Antengene Biologics Limited· Source
Contact: Peng Yan
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516· Phase 2· Peking University People's Hospital· Source
Contact: Zhenchun Zhang
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625· Harbin Medical University· Source
Contact: Yanjin Wei
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450· Phase 2· Takeda· Source
Contact: Ziran Wang (principal investigator)
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372· Beijing Anzhen Hospital· Source
Contact: Li Wei, Professor
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Zhongming Zhang, Master
Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke
NCT07423975· Phase 2· Beijing Tiantan Hospital· Source
Contact: Hao Wang, MD
Not yet recruiting
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Jinling Zhang, Master
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
NCT07520565· Phase 3· Biocells (Beijing) Biotech Co.,Ltd· Source
Contact: Ziran Wang
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Zhongmin Zhang, Doctor
Recruiting
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308· Phase 3· Capital Medical University· Source
Contact: Hao Wang
Active, not recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776· Phase 3· Capital Medical University· Source
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353· Phase 3· Cascade Pharmaceuticals, Inc· Source
Contact: Gao Feng
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493· Phase 2· Kunming Pharmaceuticals, Inc.· Source
Contact: Duo Gao, bachelor
Recruiting
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
NCT07581210· Phase 2· Shanghai QuietD Biotechnology Co., Ltd.· Source
Contact: Ziran Wang
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314· Capital Medical University· Source
Contact: Xianjun Wang
Active, not recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301· Capital Medical University· Source
Recruiting
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865· Phase 2· RemeGen Co., Ltd.· Source
Contact: Guixiang Weng
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Zhongmin Zhang, M.D.
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Feng Gao
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NCT06932068· Phase 2· Qilu Hospital of Shandong University· Source
Contact: Jinling Zhang
Active, not recruiting
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336· Phase 2· TJ Biopharma Co., Ltd.· Source
Active, not recruiting
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883· Phase 2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
NCT06663631· Phase 1· Capital Medical University· Source
Contact: Qi Wang, Dr.
Not yet recruiting
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source
Contact: Qingyu Dong, Doctor
Recruiting
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
NCT06662071· Qilu Hospital of Shandong University· Source
Contact: Zhiqiang Shao
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source
Active, not recruiting
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
NCT07169656· The First Affiliated Hospital of Zhengzhou University· Source
Contact: Feng Gao
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· Phase 2/3· Hutchmed· Source
Contact: Zhongmin Zhang
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
NCT06152107· Shanghai Chest Hospital· Source
Contact: Li Wei
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source
Contact: Guixiang Weng
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Active, not recruiting
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287· Phase 3· RemeGen Co., Ltd.· Source
Recruiting
Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific
NCT05578300· Chinese University of Hong Kong· Source
Contact: Fengyuan Che, MD,PhD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Stroke10 recruiting
Gastric and oesophageal cancer3 recruiting
Atrial fibrillation2 recruiting
Hepatitis B2 recruiting
Liver and biliary tract cancer2 recruiting
Lung cancer2 recruiting
Bladder cancer1 recruiting
Colorectal cancer1 recruiting
COPD1 recruiting
Coronary artery disease1 recruiting
Deep vein thrombosis and pulmonary embolism1 recruiting
Lupus (SLE)1 recruiting
Metastatic breast cancer1 recruiting
Obstructive sleep apnoea1 recruiting
Ovarian cancer1 recruiting
Pancreatic cancer1 recruiting
Primary biliary cholangitis1 recruiting
Rheumatoid arthritis1 recruiting
Sjögren's disease1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Type 1 diabetes1 recruiting

Closed trials

Completed
HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.
NCT07233070· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source
Completed
Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
NCT06221371· Phase 3· Beijing Tiantan Hospital· Source
Completed
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
NCT06196320· Phase 3· Beijing Tiantan Hospital· Source
Completed
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
NCT06202378· Phase 2· Shanghai Hutchison Pharmaceuticals Limited· Source
Completed
Mindfulness-based Stress Reduction Combined With Aerobic Training in Cardiac Rehabilitation After Percutaneous Coronary Intervention: A Dual Impact on Kinesiophobia and Heart Rate Variability
NCT07544459· Linyi People's Hospital· Source
Terminated
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT06106841· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Completed
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
NCT05920889· Phase 2· Chinese University of Hong Kong· Source
Completed
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
NCT05810038· Phase 3· Pfizer· Source
Completed
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source
Completed
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)
NCT05439356· Phase 3· Beijing Tiantan Hospital· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error